Myovant Sciences Ltd (MYOV)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Lynn Seely
Employees:
20
20-22 BEDFORD ROW, LONDON, UNITED KINGDOM WC1R 4JS
(441) 824-8101

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It specializes in development and commercialization of innovative therapies for women's health diseases and other endocrine-related disorders. It focuses on product candidate, relugolix, for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and advanced prostate cancer, as well as in RVT-602, for the treatment of female infertility as part of assisted reproduction. The company was founded on February 2, 2016 and is headquartered in Hamilton, Bermuda.

Data derived from most recent annual or quarterly report
Market Cap 985.062 Million Shares Outstanding93.905 Million Avg 30-day Volume 983.703 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-3.13
Price to Revenue7.3502 Debt to Equity0.0 EBITDA-204.777 Million
Price to Book Value0.0 Operating Margin-107.24560000000001 Enterprise Value927.644 Million
Current Ratio2.136 EPS Growth0.075 Quick Ratio2.032
1 Yr BETA 1.8092 52-week High/Low 27.43 / 7.67 Profit Margin-115.1755
Operating Cash Flow Growth-158.8319 Altman Z-Score-2.1046 Free Cash Flow to Firm -249.559 Million
View SEC Filings from MYOV instead.

View recent insider trading info

Myovant Sciences Ltd YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding MYOV (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MYOV BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

48.6 Thousand total shares from 6 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MAREK DAVID C PRINCIPAL EXECUTIVE OFFICER

  • Officer
  • Director
 447,956 2022-04-19 3

LANG MATTHEW GENERAL COUNSEL & CORP. SECY.

  • Officer
 276,037 2022-04-19 6

ARJONA FERREIRA JUAN CAMILO CHIEF MEDICAL OFFICER

  • Officer
 260,129 2022-04-19 12

MERENDINO LAUREN CHIEF COMMERCIAL OFFICER

  • Officer
 174,953 2022-04-19 2

MEHRA UNEEK PRINCIPAL FINANCIAL OFFICER

  • Officer
 214,180 2022-04-15 3

POTTER MYRTLE S

  • Director
 21,096 2021-11-05 1

GUINAN MARK

  • Director
 21,096 2021-11-05 1

GULFO ADELE M.

  • Director
 21,096 2021-11-05 1

CURRAN TERRIE

  • Director
 21,096 2021-11-05 3

VALENTE NANCY

  • Director
 0 2021-11-05 2

SUMITOMO CHEMICAL CO., LTD.

DAINIPPON SUMITOMO PHARMA CO LTD

SUMITOVANT BIOPHARMA LTD.

  • 10% Owner
 50,041,181 2021-09-28 16

KARBE FRANK PRINCIPAL FIN'L & ACCOUNTING

  • Officer
 212,296 2021-07-07 1

SEBELIUS KATHLEEN

  • Director
 0 2020-09-15 0

SEELY LYNN PRINCIPAL EXECUTIVE OFFICER

  • Officer
  • Director
 1,889,992 2020-04-03 0

SABLICH KIM CHIEF COMMERCIAL OFFICER

  • Officer
 146,710 2020-04-03 0

ROIVANT SCIENCES LTD.

  • 10% Owner
 No longer subject to file 2019-12-27 0

NOMURA HIROSHI

  • Director
 0 2019-12-27 0

TORTI FRANK

  • Director
 0 2019-08-23 0

VIKING GLOBAL PERFORMANCE LLC

VIKING GLOBAL EQUITIES LP

VIKING GLOBAL EQUITIES II LP

VGE III PORTFOLIO LTD.

VIKING GLOBAL EQUITIES MASTER LTD.

VIKING LONG FUND GP LLC

VIKING LONG FUND MASTER LTD.

HALVORSEN OLE ANDREAS

OTT DAVID C.

SHABET ROSE SHARON

  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
 No longer subject to file 2019-07-10 0

VIKING GLOBAL INVESTORS LP

VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

VIKING GLOBAL OPPORTUNITIES GP LLC

HALVORSEN OLE ANDREAS

OTT DAVID C.

SHABET ROSE SHARON

  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
 No longer subject to file 2019-07-10 0

QVT ASSOCIATES GP LLC

QVT FUND V LP

  • Director
  • 10% Owner
  • SEE REMARKS
 No longer subject to file 2019-07-10 0

MACHADO PATRICK

  • FORMER 10% OWNER
 No longer subject to file 2019-07-10 0

DEXXON HOLDINGS LTD.

DEXCEL PHARMA TECHNOLOGIES LTD.

OREN DAN

  • SEE REMARKSSEE REMARKSSEE REMARKS
 No longer subject to file 2019-07-10 0

LO ANDREW

  • FORMER 10% OWNER
 No longer subject to file 2019-07-10 0

SVF INVESTMENTS (UK) LTD

SOFTBANK VISION FUND L.P.

SVF HOLDINGS (UK) LLP

SVF GP (JERSEY) LTD

  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
 No longer subject to file 2019-07-10 0

VIKING GLOBAL EQUITIES MASTER LTD.

  • 10% Owner
 38,341,357 2019-01-01 0

ALTMEYER MARK

  • Director
 0 2018-08-31 0

VIKING GLOBAL PERFORMANCE LLC

VIKING GLOBAL EQUITIES LP

VIKING GLOBAL EQUITIES II LP

VGE III PORTFOLIO LTD.

VIKING LONG FUND MASTER LTD.

VIKING LONG FUND GP LLC

  • 10% Owner
 38,341,357 2018-04-02 0

MILLENNIUM PHARMACEUTICALS INC

TAKEDA PHARMACEUTICALS U.S.A., INC.

  • 10% Owner
 7,420,625 2018-03-19 0

TAKEDA PHARMACEUTICALS INTERNATIONAL AG

TAKEDA PHARMACEUTICAL CO LTD

TAKEDA A/S

TAKEDA EUROPE HOLDINGS B.V.

TAKEDA PHARMA A/S

  • 10% Owner
 7,420,625 2018-03-19 0

DEXCEL PHARMA TECHNOLOGIES LTD.

  • 10% Owner
 37,231,342 2017-09-06 0

DEVEYDT WAYNE S

  • Director
 0 2017-08-18 0

SHABET ROSE SHARON

  • 10% Owner
 37,231,342 2017-07-01 0

TAKEDA PHARMACEUTICALS INTERNATIONAL AG

  • 10% Owner
 7,420,625 2017-04-17 0

VIKING GLOBAL INVESTORS LP

VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

VIKING GLOBAL OPPORTUNITIES GP LLC

HALVORSEN OLE ANDREAS

OTT DAVID C.

SUNDHEIM DANIEL S.

  • 10% Owner
 37,231,342 2016-10-26 0

MANCHESTER KEITH S

  • Director
 0 2016-10-26 0

RAMASWAMY VIVEK

  • Director
 0 2016-10-26 0

DEXXON HOLDINGS LTD.

OREN DAN

  • 10% Owner
 37,231,342 2016-10-26 0

ROMEO MARIANNE L. HEAD,GLOBAL TRANS. & RISK MGMT

  • Officer
 0 2016-10-26 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

ARJONA FERREIRA JUAN CAMILO - Officer CHIEF MEDICAL OFFICER

2022-04-21 16:27:06 -0400 2022-04-19 S 4,632 $10.45 d 260,129 direct 8.8486 -0.7463 8.8486 2 -2.2388 4

LANG MATTHEW - Officer GENERAL COUNSEL & CORP. SECY.

2022-04-21 16:28:08 -0400 2022-04-19 S 8,002 $10.45 d 276,037 direct 8.8486 -0.7463 8.8486 2 -2.2388 4

MAREK DAVID C - Director - Officer PRINCIPAL EXECUTIVE OFFICER

2022-04-21 16:25:00 -0400 2022-04-19 S 24,594 $10.45 d 447,956 direct 8.8486 -0.7463 8.8486 2 -2.2388 4

MERENDINO LAUREN - Officer CHIEF COMMERCIAL OFFICER

2022-04-21 16:25:57 -0400 2022-04-19 S 7,049 $10.45 d 174,953 direct 8.8486 -0.7463 8.8486 2 -2.2388 4

MAREK DAVID C - Director - Officer PRINCIPAL EXECUTIVE OFFICER

2022-04-19 16:46:56 -0400 2022-04-15 A 134,567 a 472,550 direct -5.6436 -9.2079 1.0891 4 -9.2079 6

ARJONA FERREIRA JUAN CAMILO - Officer CHIEF MEDICAL OFFICER

2022-04-19 16:51:02 -0400 2022-04-15 A 103,703 a 264,761 direct -5.6436 -9.2079 1.0891 4 -9.2079 6

MERENDINO LAUREN - Officer CHIEF COMMERCIAL OFFICER

2022-04-19 16:48:43 -0400 2022-04-15 A 103,703 a 182,002 direct -5.6436 -9.2079 1.0891 4 -9.2079 6

LANG MATTHEW - Officer GENERAL COUNSEL & CORP. SECY.

2022-04-19 16:49:41 -0400 2022-04-15 A 111,111 a 284,039 direct -5.6436 -9.2079 1.0891 4 -9.2079 6

MAREK DAVID C - Director - Officer PRINCIPAL EXECUTIVE OFFICER

2022-04-19 16:46:56 -0400 2022-04-15 A 204,808 a 204,808 direct

MEHRA UNEEK - Officer PRINCIPAL FINANCIAL OFFICER

2022-04-19 16:52:15 -0400 2022-04-15 A 111,111 a 214,180 direct -5.6436 -9.2079 1.0891 4 -9.2079 6

ARJONA FERREIRA JUAN CAMILO - Officer CHIEF MEDICAL OFFICER

2022-04-07 16:16:51 -0400 2022-04-05 S 1,922 $13.78 d 161,058 direct -4.3448 -25.1034 0.0 1 -28.3448 3

LANG MATTHEW - Officer GENERAL COUNSEL & CORP. SECY.

2022-04-07 16:19:29 -0400 2022-04-05 S 2,436 $13.78 d 172,928 direct -4.3448 -25.1034 0.0 1 -28.3448 3

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
MYOVANT SCIENCES LTD MYOV 2022-05-20 22:15:03 UTC 0.3726 0.4474 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 21:45:03 UTC 0.3726 0.4474 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 21:15:03 UTC 0.3726 0.4474 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 20:45:03 UTC 0.3728 0.4472 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 20:15:05 UTC 0.3728 0.4472 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 19:45:03 UTC 0.3728 0.4472 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 19:15:04 UTC 0.3728 0.4472 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 18:45:03 UTC 0.3728 0.4472 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 18:15:03 UTC 0.3728 0.4472 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 17:45:03 UTC 0.3728 0.4472 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 17:15:03 UTC 0.3728 0.4472 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 16:45:04 UTC 0.3285 0.4915 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 16:15:03 UTC 0.3285 0.4915 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 15:45:03 UTC 0.3285 0.4915 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 15:15:03 UTC 0.3285 0.4915 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 14:45:03 UTC 0.2123 0.6077 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 14:15:04 UTC 0.2123 0.6077 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 13:45:03 UTC 0.2123 0.6077 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 13:15:03 UTC 0.2123 0.6077 600000
MYOVANT SCIENCES LTD MYOV 2022-05-20 12:45:03 UTC 0.2123 0.6077 600000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Enhanced Index Plus Fund MYOV -302.0 shares, $-2280.1 2020-03-31 N-PORT
FundVantage Trust- Gotham Defensive Long Fund MYOV -2.0 shares, $-15.1 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund MYOV -297.0 shares, $-2242.35 2020-03-31 N-PORT

Elevate your investments